Panavance Therapeutics is a privately held, clinical-stage pharmaceutical company developing a novel oncology asset, misetionamide (also known as GP-2250). Panavance, a US Delaware company located in Berwyn, PA, was founded in 2021 as wholly owned carve out of the Geistlich group, a family-owned Swiss company, to focus on misetionamide and the oncology business.​

Misetionamide is a broadly active small molecule with a novel mechanism of action that inhibits two oncogenic transcription factors, c-MYC and NFκB. Acting through c-MYC, misetionamide selectively disrupts the energy metabolism of cancer cells leading to cancer cell death. Through NFκB inhibition, misetionamide inhibits cancer cells’ ability to proliferate and survive. This dual target mechanism makes misetionamide an attractive tumor cell selective agent. ​

Panavance is currently conducting a multicenter phase 1 dose escalation trial in four US clinical sites. The company plans to initiate a clinical trial of misetionamide for the treatment of platinum-resistant ovarian cancer and a clinical trial as a first-line maintenance therapy for non-BRCA mutated pancreatic cancer patients, a population for which there are no FDA approved drugs. Extensive preclinical studies have demonstrated that misetionamide’s broadly anti-neoplastic MOA has the potential to be effective in additional tumor types, including melanoma, squamous cell, breast, and colorectal cancers.​